Scientific Sessions 2024  /  From Intervention to Prevention: Advances in Coronary and Valvular Heart Disease  /  Discussant: ENBALV
Logo

American Heart Association

  111
  0

Final ID:

Discussant: ENBALV

  • Windecker, Stephan  ( Swiss Cardiovascular Center Bern , Bern , Switzerland )
  • Steg, Philippe  ( Hopital Bichat , Paris , France )
    • Author Disclosures:
    Stephan Windecker: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Abbott, Abiomed, Amgen, Astra Zeneca, Bayer Bbraun Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb:Active (exists now) ; Other (please indicate in the box next to the company name):Termumo, Vifor, V-Wave:Active (exists now) ; Other (please indicate in the box next to the company name):Novartis, NovoNordisk, Organon, OrPha Suisse, Pharming Tech, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed:Active (exists now) ; Other (please indicate in the box next to the company name):Guerbet, Idorsia, Inari Medical, InfraRedx, Jannssen Cilag, Jonhon&Johnson, Medalliance, Medicure, Medtronic, Merck Sharp&Dohm, Miracor Medical:Active (exists now) ; Other (please indicate in the box next to the company name):Carindal Health, CardioValve, Cordis Medical, Corflow Therapeutics, CSL Behring, Daichi Sankyo, Edwards Lifesciences, Farapulse Inc., Fumedica:Active (exists now) | Philippe Steg: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Consultant:Idorsia:Active (exists now) ; Consultant:BMS:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Ownership Interest:Bioquantis:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Consultant:Amarin:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

From Intervention to Prevention: Advances in Coronary and Valvular Heart Disease

Sunday, 11/17/2024 , 08:00AM - 09:15AM

Late-Breaking Science

More abstracts on this topic:
Efficacy of a Glucagon-Like Peptide-1 Agonist in Patients undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement – a randomized clinical trial

Kjaergaard Jesper, Boesgaard Soeren, Kober Lars, Nilsson Jens Christian, Hassager Christian, Moeller Christian Holdflod, Wiberg Sebastian, Mikkelsen Astrid, Møller-sørensen Peter Hasse, Ravn Hanne Berg, Ravn Jesper, Olsen Peter Skov, Høfsten Dan

From STICH to GLORIOUS: The evolution of coronary interventions

Chikwe Joanna, Farkouh Michael

More abstracts from these authors:
Heart Block, the Nuisance of TAVR: When to place PPM pre-procedure, post-procedure, or just monitor at home?

Boskovski Marko, Windecker Stephan, Tang Gilbert, Van Mieghem Nicolas, Rodes-cabau Josep, Sondergaard Lars, Barbanti Marco

Association of the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients with Diabetes and Kidney Disease: A Secondary Analysis of the SCORED Trial

Odutayo Ayodele, Cherney David, Bhatt Deepak, Sridhar Vikas, Szarek Michael, Davies Michael, Banks Phillip, Girard Manon, Pitt Bertram, Steg Philippe

You have to be authorized to contact abstract author. Please, Login
Not Available